

Jennifer Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3274749/publications.pdf>

Version: 2024-02-01

16
papers

310
citations

1307594

7
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

354
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 305.	3.7	56
2	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 6037.	12.8	51
3	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. <i>Journal of Controlled Release</i> , 2018, 270, 158-176.	9.9	49
4	Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. , 2022, 10, e003975.		33
5	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. <i>Leukemia</i> , 2021, 35, 2346-2357.	7.2	28
6	Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy. <i>Pharmaceutical Research</i> , 2019, 36, 144.	3.5	26
7	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	11
8	CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. <i>Leukemia Research Reports</i> , 2021, 16, 100268.	0.4	10
9	Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. <i>Cancers</i> , 2021, 13, 2853.	3.7	9
10	Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 1878-1885.	1.8	8
11	Liposomal phytohemagglutinin: In vivo Tâ€cell activator as a novel panâ€cancer immunotherapy. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 940-944.	3.6	7
12	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 19343.	3.3	6
13	Biomaterials for cancer immunotherapy. , 2020, , 499-526.		5
14	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	1.3	5
15	P-079: IL10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S82.	0.4	3
16	Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma. <i>Blood</i> , 2020, 136, 3-3.	1.4	3